![](https://investorshub.advfn.com/uicon/529502.png?cb=1651683647)
Thursday, January 14, 2016 7:20:42 PM
From the PR:
Announce new partnerships or collaborations with academic, biotechnology and/or big pharma (Q1 2016)
IND response to the FDA comments for dCellVax (Q2 2016)
Initial IND submission to the FDA for inhibition of NR2F6 in an indication to be determined (Q2 2016)
Begin HemaXellerate clinical trial (Q3 2016)
Identify small molecule inhibitor of NR2F6 (Q3 2016)
Let's see what transpires this quarter. My bet we'll see academic collaborations which are nice but doesn't put money in Regen's pockets.
The one that would most likely move the pps up is a partnership with a well known pharma. Let's see if Landers can get that done.
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM